Abstract
SEVERITY ASSESSMENT OF ADVERSE DRUG REACTION AND QUALITY OF LIFE OF DYSLIPIDEMIA PATIENTS ON ATORVASTATIN OR ROSUVASTATIN V/S CONTROLLED.

Shilpa Sah*, Dr. Yusra Ahmad and Dr. Puneet Dhameja

ABSTRACT

Background: Adverse drug reaction and quality of life is most important in terms of patient health, by analyzing these two parameters there must be improvement in dyslipidemia patients. Method: Rosuvastatin and Atorvastatin were used for the study. A total no. of 60 patients with dyslipidemia was taken and age group of 30-90 years. Total patient were divided into two groups. Atorvastatin drug given to group I and Rosuvastatin to group II. Study was carried out for six months.Inclusion criteria: Dyslipidemia, Age above 18, both sexes, Patient having multiple risk factors for heart diseases. Exclusion Criteria: History of myalgia, Hyersensitive to Atorvastatin or Rosuvastatin, Pregnancy and lactation, Woman on oral contraceptives, patient with abnormal liver function and abnormal renal function. While taking patient history, Questionnaire for quality of life has been prepared as per W.H.O guidelines.SF-36 was followed for both groups. Result: From total 60 patients, 70% were male and 30% were female. Total percentage of adverse drug reaction in group I, mild (51.72), moderate (44.8), severe (3.45) and for group II, mild (6.89), moderate (86.2), severe (6.89) and overall adverse drug reactions in percentage by both drugs were 58.61 for mild, 13.1 moderate and 10.34 severe. Quality of life was better shown in group II (Rosuvastatin) than group I (Atorvastain) and adverse drug reaction was shown less in group I (Atorvastatin). Conclusion: In future, study can be done on the basis of molecular and biochemical mechanisms of myopathy and rhabdomyolysis by statins as well as on Atherogenic Dyslipidemia.

Keywords: Quality of Life, Adverse Drug Reaction, Dyslipidemia.


[Full Text Article]   [Download Certificate]

Login





Forgot Password  |  Register

Indexing

Best Paper Awards

European Journal of Biomedical and Pharmaceutical Sciences (EJBPS) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.

Best Article of current issue :

Dr. Dhrubo Jyoti Sen

Download Article : Click here

News & Updation

  • EJBPS New Impact Factor

    EJBPS Impact Factor has been Increased to 7.482 for Year 2024.

  • EJBPS: FEBRUARY ISSUE PUBLISHED

    FEBRUARY 2024 Issue has been successfully launched on 1 FEBRUARY 2024.

  • Index Copernicus Value

    EJBPS Received Index Copernicus Value 77.3, due to High Quality Publication in EJBPS at International Level

  • Journal web site support Internet Explorer, Google Chrome, Mozilla Firefox, Opera, Saffari for easy download of article without any trouble.

    .

  • Article Invited for Publication

    Dear Researcher, Article Invited for Publication  in EJBPS coming Issue.

     

UG/PG/Ph.D Research Publication

Research Scholar of UG/PG/Ph.D can Submit their Research Article/Review Article/Case Study/Short Communication for Publication in EJBPS

Downloads

Copyright From

Covering Letter

                        Author Instruction 
 

PLAGERLUM REPORT